ArticleWorld journal of pediatric surgery2026
Dual-stage deep learning framework for neuroblastoma differentiation by integrating cell segmentation and multiscale modeling.
Article in World journal of pediatric surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the most common extracranial solid tumor in children, accurate and consistent pathological diagnosis of neuroblastoma (NB) is critical for clinical decision-making. However, traditional methods relying on manual interpretation are constrained by tumor heterogeneity and inter-observer variability, necessitating the development of objective and quantitative intelligent auxiliary diagnostic technologies. Methods: This study introduces a two-stage deep learning framework with hybrid supervision, achieving precise classification of NB through collaborative optimization of cell-level segmentation and multiscale classification. In the first stage, the enhanced Medical Segment Anything Model (MedSAM) uses a cross-attention mechanism to achieve pixel-level tumor cell segmentation, attaining a Dice coefficient of 0.94. In the second stage, an optimized Swin Transformer (ST) is employed to construct the classification network, enabling full slice analysis via a confidence voting strategy. Results: On an independent dataset comprising 185 whole-slide images from 185 patients, the model attained an overall area under the receiver operating characteristic curve (AUC) of 0.864 (95% confidence interval (CI): 0.747 to 0.952), significantly outperforming existing methods (8.7% higher than the second-best model, ResNeXt). Among the three NB subtypes (undifferentiated, poorly differentiated, and differentiating), the recognition accuracy is the highest for the poorly differentiated subtype, which accounts for the largest proportion in clinical practice. Conclusion: This approach effectively addresses issues related to the tumor microenvironment interference and small-sample generalization through a cascaded feature extraction and decision-making mechanism, providing a robust intelligent auxiliary tool for NB pathological diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.